account/PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it entered into a definitive agreement to acquire privately-held Edict Pharmaceuticals, an India-based developer and manufacturer of generic pharmaceuticals, for up to $37...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Par Pharmaceutical To Acquire Edict Pharmaceuticals
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account